BioSpace News Archive

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the Company has reached alignment with the U.S. Food and Drug Administration (FDA) on a pivotal study design for lumasiran, an investigational RNAi therapeutic for the treatment of primary hyperoxaluria type 1 (PH1).

RTI Surgical, Inc. reported operating results for the first quarter of 2018.

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, announced today an exclusive licensing agreement with The University of Texas MD Anderson Cancer Center for intellectual property related to certain methods of use of poziotinib.

GlycoMimetics, Inc. reported its financial results for the first quarter ended March 31, 2018 and highlighted recent company achievements.

Entac Medical Inc. announced that it has completed its Series A2 round of financing.

Insulet Corporation announced that it has achieved key milestones as it transitions to direct operations in Europe on July 1st.

BD (Becton, Dickinson and Company) reported quarterly revenues of $4.222 billion for the second fiscal quarter ended March 31, 2018.

DowDuPont Reports First Quarter 2018 Results

A new survey reveals that 74 percent of people have personally seen a handicap accessible parking space being improperly used.

Intact Vascular, Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, today announced that its Tack Optimized Balloon Angioplasty III (TOBA III) clinical trial has completed enrollment.